Cited by 2,292Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.

C-Reactive Protein Levels and Outcomes after Statin Therapy

Open access

Ridker, Paul M, Cannon, Christopher P., Morrow, David, Rifai, Nader, Rose, Lynda M., McCabe, Carolyn H., Pfeffer, Marc A., Braunwald, Eugene·2005·New England Journal of Medicine

DOI 10.1056/nejmoa042378

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown. METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. RESULTS: Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years). CONCLUSIONS: Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa042378

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Self-citation
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,354
Effect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Self-citation
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Self-citation

Flagged first, then by citations

Show all 28 references

Research works printed but not linked: 1

Davignon J, 2004, Circulation, 109, III

Sorted by citations

Items 301–400 of 1,000

Cardiovascular co-morbidity in rheumatic diseases
Turesson, C. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s2453 · Cited by 129
PCSK9 inhibition and inflammation: A narrative review
Ruscica, M., Tokgözoğlu, L. S., Corsini, A., & Sirtori, C. R. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.07.015 · Cited by 133
Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial
Raju, N. C., Yi, Q., Nidorf, M., Fagel, N. D., Hiralal, R., & Eikelboom, J. W. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0637-y · Cited by 129
ApoE Plasma Levels and Risk of Cardiovascular Mortality in Old Age
Mooijaart, S. P., Berbée, J. F. P., van Heemst, D., Havekes, L. M., de Craen, A. J. M., Slagboom, P. E., Rensen, P. C. N., & Westendorp, R. G. J. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030176 · Cited by 129
Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, Diabetes, and Total Mortality: Implications for Longevity
Ridker, P. M. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00372.x · Cited by 132
Self-citation
C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
Sattar, N. A., Murray, H. M., McConnachie, A., Blauw, G. J., Bollen, E. L. E. M., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.643114 · Cited by 129
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein
Ridker, P. M., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Khurmi, N. S., Köenig, W., Libby, P., Lorenzatti, A. J., Nordestgaard, B. G., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.072 · Cited by 125
Self-citation
Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging
Kornman, K. S. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.475s · Cited by 127
Pediatric Precursors of Adult Cardiovascular Disease: Noninvasive Assessment of Early Vascular Changes in Children and Adolescents
Groner, J. A., Joshi, M. S., & Bauer, J. A. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2992 · Cited by 122
Reduced-calorie orange juice beverage with plant sterols lowers C-reactive protein concentrations and improves the lipid profile in human volunteers
Devaraj, S., Autret, B. C., & Jialal, I. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.4.756 · Cited by 125
C-reactive protein in peripheral arterial disease: Relation to severity of the disease and to future cardiovascular events
Vainas, T., Stassen, F. R. M., de GRAAF, R., Twiss, E. L. L., Herngreen, S. B., Welten, R. J. T. J., van den Akker, L. H. J. M., van Dieijen‐Visser, M. P., Bruggeman, C. A., & Kitslaar, P. J. E. H. M. (2005) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2005.03.060 · Cited by 125
Interactions between chronic renal disease and periodontal disease
Craig, R. (2007) · Oral Diseases · doi:10.1111/j.1601-0825.2007.01430.x · Cited by 126
Statins, systemic inflammation and risk of death in COPD: The Rotterdam study
Lahousse, L., Loth, D. W., Joos, G., Albert Hofman, D., Leufkens, H. G. M., Brusselle, G., & Stricker, B. H. C. (2012) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2012.10.008 · Cited by 124
C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy
Puri, R., Nissen, S. E., Libby, P., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Raichlen, J. S., Uno, K., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.004243 · Cited by 124
Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond
Aday, A. W., & Ridker, P. M. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00062 · Cited by 131
Self-citation
CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health
Cota, D. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.764 · Cited by 134
Statin Use and Hospitalization for Sepsis in Patients With Chronic Kidney Disease
Gupta, R., Plantinga, L., Fink, N. E., Melamed, M. L., Coresh, J., Fox, C. S., Levin, N. W., & Powe, N. R. (2007) · JAMA · doi:10.1001/jama.297.13.1455 · Cited by 121
Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease
Nicholls, S. J., Ray, K. K., Johansson, J. O., Gordon, A., Sweeney, M., Halliday, C., Kulikowski, E., Wong, N. C. W., Kim, S. W., & Schwartz, G. G. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0250-3 · Cited by 123
Relationship Between Uncontrolled Risk Factors and C-Reactive Protein Levels in Patients Receiving Standard or Intensive Statin Therapy for Acute Coronary Syndromes in the PROVE IT-TIMI 22 Trial
Ray, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Rifai, N., Kirtane, A. J., McCabe, C. H., Skene, A. M., Gibson, C. M., Ridker, P. M., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.024 · Cited by 123
Self-citation
High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities
Fonseca, F. A. H., & Izar, M. C. D. O. (2016) · Clinics · doi:10.6061/clinics/2016(04)11 · Cited by 123
Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome
Mani, P., Puri, R., Schwartz, G. G., Nissen, S. E., Shao, M., Kastelein, J. J. P., Menon, V., Lincoff, A. M., & Nicholls, S. J. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0179 · Cited by 128
Toward Immunomodulatory and Anti-Inflammatory Properties of Statins
Arnaud, C., Braunersreuther, V., & Mach, F. (2005) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2005.07.002 · Cited by 123
Microcirculation and oxidative stress
Crimi, E., Ignarro, L. J., & Claudio Napoli, A. (2007) · Free Radical Research · doi:10.1080/10715760701732830 · Cited by 123
Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study
Wethal, T., Lund, M.-B., Edvardsen, T., Fosså, S. D., Pripp, A. H., Holte, H., KJEKSHUS, J. K., & Fosså, A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605191 · Cited by 120
Effect of 24 Weeks of Statin Therapy on Systemic and Vascular Inflammation in HIV-Infected Subjects Receiving Antiretroviral Therapy
Eckard, A. R., Jiang, Y., Debanne, S. M., Funderburg, N., & McComsey, G. A. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu012 · Cited by 122
Effect of Intensive Lipid Lowering on Progression of Coronary Atherosclerosis: Evidence for an Early Benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Trial
Nissen, S. E. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.013 · Cited by 119
Inflammation, Atherosclerosis, and Stroke
Elkind, M. S. V. (2006) · The Neurologist · doi:10.1097/01.nrl.0000215789.70804.b0 · Cited by 120
Cardiovascular Risk Prediction in Patients With Stable and Unstable Coronary Heart Disease
Morrow, D. A. (2010) · Circulation · doi:10.1161/circulationaha.109.852749 · Cited by 119
Self-citation
Management of Cardiovascular Disease in Renal Transplant Recipients
Shirali, A. C., & BIA, M. J. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05081107 · Cited by 119
Effect of C-reactive protein reduction on paroxysmal atrial fibrillation
Dernellis, J. M., & Panaretou, M. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.06.032 · Cited by 119
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel, T. N., Shishehbor, M. H., & Bhatt, D. L. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl445 · Cited by 119
Effect of Fluvastatin on Progression of Coronary Atherosclerotic Plaque Evaluated by Virtual Histology Intravascular Ultrasound
Nasu, K., Tsuchikane, E., Katoh, O., Tanaka, N., Kimura, M., Ehara, M., Kinoshita, Y., Matsubara, T., Matsuo, H., Asakura, K., et al. (2009) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.04.016 · Cited by 119
Statin Use and Risk of COPD Exacerbation Requiring Hospitalization
Wang, M., Lo, Y.-W., Tsai, C., Chang, L.-C., Malone, D. C., Chu, C.-L., & Liou, J. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.01.036 · Cited by 117
A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study†
Stalenhoef, A. F. H., Ballantyne, C. M., Sarti, C., Murín, J., Tonstad, S., Rose, H., & Wilpshaar, W. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi482 · Cited by 116
Effect of monoclonal antibodies to PCSK9 on high‐sensitivity C‐reactive protein levels: a meta‐analysis of 16 randomized controlled treatment arms
Sahebkar, A., Di Giosia, P., Stamerra, C. A., Grassi, D., Pedone, C., Ferretti, G., Bacchetti, T., Ferri, C., & Giorgini, P. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12905 · Cited by 116
Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study
Nantz, M. P., Rowe, C. A., Bukowski, J. F., & Percival, S. S. (2008) · Nutrition · doi:10.1016/j.nut.2008.07.018 · Cited by 116
Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology
Tuñón, J., Badimón, L., Bochaton‐Piallat, M., Cariou, B., Daemen, M. J. A. P., Egido, J., Evans, P. C., Hoefer, I. E., Ketelhuth, D. F. J., Lutgens, E., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy293 · Cited by 118
A Randomized Trial of the Efficacy and Safety of Fenofibrate versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities: AIDS Clinical Trials Group Study 5087
Aberg, J. A., Zackin, R. A., Brobst, S. W., Evans, S. R., Alston, B., Henry, W. K., Glesby, M. J., Torriani, F. J., Yang, Y., Owens, S., et al. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.757 · Cited by 115
Roles of Growth Differentiation Factor 15 in Atherosclerosis and Coronary Artery Disease
Wang, J., Wei, L., Yang, X., & Zhong, J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012826 · Cited by 117
Metabolic syndrome: the danger signal in atherosclerosis
Mathieu, P., Pîbarot, P., & Després, J. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.285 · Cited by 117
Long-term prognosis in patients with psoriasis
Gulliver, W. P. F. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08779.x · Cited by 114
Noninvasive Detection of Subclinical Coronary Atherosclerosis Coupled With Assessment of Changes in Plaque Characteristics Using Novel Invasive Imaging Modalities
van Mieghem, C. A. G., McFadden, E. P., de Feyter, P. J., Bruining, N., Schaar, J. A., Mollet, N. R., Cademartiri, F., Goedhart, D. M., de Winter, S., Rodríguez-Granillo, G. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.075 · Cited by 112
Cardiac Biomarkers: What Is and What Can Be
Jacob, R. T., & Khan, M. (2018) · Indian Journal of Cardiovascular Disease in Women · doi:10.1055/s-0039-1679104 · Cited by 113
Statins and Inflammation
Satny, M., Hubacek, J. A., & Vrablík, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00977-6 · Cited by 121
Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events
Feinbloom, D. B., & Bauer, K. A. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000181762.31694.da · Cited by 112
The effects of garlic extract upon endothelial function, vascular inflammation, oxidative stress and insulin resistance in adults with type 2 diabetes at high cardiovascular risk. A pilot double blind randomized placebo controlled trial
Atkin, M., Laight, D. W., & Cummings, M. H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.01.003 · Cited by 115
Persistently raised C‐reactive protein levels are associated with advanced periodontal disease
Linden, G. J., McClean, K., Young, I. S., Evans, A., & Kee, F. (2008) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2008.01288.x · Cited by 112
Vitamin C treatment reduces elevated C-reactive protein
Block, G., Jensen, C. D., Dalvi, T. B., Norkus, E. P., Hudes, M. L., Crawford, P. B., Holland, N., Fung, E. B., Schumacher, L. B., & Harmatz, P. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.030 · Cited by 114
Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization
Smith, G. D., Timpson, N. J., & Ebrahim, S. B. J. (2008) · Annals of Medicine · doi:10.1080/07853890802010709 · Cited by 112
Mechanisms of obesity and related pathologies: Androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction
Traish, A. M., Feeley, R. J., & Guay, A. T. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07305.x · Cited by 115
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective
KONES, R. J. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s10812 · Cited by 112
Inflammatory markers in coronary heart disease
Madjid, M., & Willerson, J. T. (2011) · British Medical Bulletin · doi:10.1093/bmb/ldr043 · Cited by 114
Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
Ahmed, S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl220 · Cited by 110
The Protective Effect of Antioxidants Consumption on Diabetes and Vascular Complications
Dal-Ros, S., & Sigrist, S. (2016) · Diseases · doi:10.3390/diseases4030024 · Cited by 117
C‐reactive protein, obesity, and the risk of arterial and venous thrombosis
Horvei, L. D., Grimnes, G., Hindberg, K., Mathiesen, E. B., Njølstad, I., Wilsgaard, T., Brox, J. H., Brækkan, S. K., & Hansen, J. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13369 · Cited by 114
Cardiovascular Abnormalities in Patients with Major Depressive Disorder
Brown, A. D. H., Barton, D. A., & Lambert, G. W. (2009) · CNS Drugs · doi:10.2165/00023210-200923070-00004 · Cited by 111
Statins and inflammation: an update
Quist‐Paulsen, P. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283398e53 · Cited by 113
The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome
Thoenes, M., Oguchi, A., Nagamia, S. H., Vaccari, C. S., Hammoud, R., Umpierrez, G. E., & Khan, B. V. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01597.x · Cited by 108
Noninvasive In Vivo Imaging of Monocyte Trafficking to Atherosclerotic Lesions
Kircher, M. F., Grimm, J., Świrski, F. K., Libby, P., Gerszten, R. E., Allport, J. R., & Weissleder, R. (2008) · Circulation · doi:10.1161/circulationaha.107.719765 · Cited by 110
Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease—A randomized placebo-controlled study
Fernandes, J. L., de Oliveira, R. T. D., Mamoni, R. L., Coelho, O. R., Nicolau, J. C., Blotta, M. H. S. L., & Junior, C. V. S. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.032 · Cited by 108
Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study
Meyer, J. M., McEvoy, J. P., Davis, V. G., GOFF, D. C., Nasrallah, H. A., Thomas, S., Hsiao, J., Swartz, M. S., Stroup, T. S., & Lieberman, J. A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.06.005 · Cited by 109
Inflammation and Infection Do Not Promote Arterial Aging and Cardiovascular Disease Risk Factors among Lean Horticulturalists
Gurven, M., Kaplan, H., Winking, J., Eid Rodriguez, D., Vasunilashorn, S., Kim, J. K., Finch, C., & Crimmins, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006590 · Cited by 107
Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
Hetherington, I., & Totary-Jain, H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.024 · Cited by 119
Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease
Osman, R., L’Allier, P. L., Elgharib, N. Z., & Tardif, J. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.221 · Cited by 111
Epidemiology and stratification of risk for sudden cardiac death
Podrid, P. J., & Myerburg, R. J. (2009) · Clinical Cardiology · doi:10.1002/clc.4960281303 · Cited by 107
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients
Catapano, A. L., Davidson, M. H., Ballantyne, C. M., Brady, W. E., Gazzara, R. A., Tomassini, J. E., & Tershakovec, A. M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132721 · Cited by 108
Inflammatory Bowel Disease Is Not a Risk Factor for Cardiovascular Disease Mortality: Results from a Systematic Review and Meta-Analysis
Dorn, S. D., & Sandler, R. S. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.01018.x · Cited by 106
C-reactive protein at the interface between innate immunity and inflammation
Peisajovich, A., Marnell, L. L., Mold, C., & Clos, T. W. D. (2008) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.4.3.379 · Cited by 110
Effects of phytosterols on markers of inflammation: A systematic review and meta-analysis
Rocha, V. Z., Ras, R. T., Gagliardi, A. C. M., Mangili, L. C., Trautwein, E. A., & Santos, R. D. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.035 · Cited by 106
The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease
Feringa, H. H. H., Karagiannis, S. E., van Waning, V. H., Boersma, E. H., Schouten, O., Bax, J. J., & Poldermans, D. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.01.024 · Cited by 106
Deletion of the phosphoinositide 3-kinase p110γ gene attenuates murine atherosclerosis
Chang, J. D., Sukhova, G. K., Libby, P., Shvartz, E., Lichtenstein, A. H., Field, S. J., Kennedy, C. E., Madhavarapu, S., Luo, J., Wu, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702663104 · Cited by 103
C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis
Leuzzi, G., Galeone, C., Taverna, F., Suatoni, P., Morelli, D., & Pastorino, U. (2017) · European Respiratory Review · doi:10.1183/16000617.0070-2016 · Cited by 104
Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology
Wong, N. D., Toth, P. P., & Amsterdam, E. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.013 · Cited by 105
Noninvasive assessment of preclinical atherosclerosis
Lane, H. A., Smith, J. C., & Davies, J. S. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.1.19 · Cited by 104
Role of Cell Adhesion Molecules and Immune-Cell Migration in the Initiation, Onset and Development of Atherosclerosis
Zhang, C., & Melendez, A. J. (2007) · Cell Adhesion & Migration · doi:10.4161/cam.1.4.5321 · Cited by 106
Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome
Gallone, G., Baldetti, L., Pagnesi, M., Latib, A., Colombo, A., Libby, P., & Giannini, F. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.052 · Cited by 104
Biomarker discovery and development in pediatric critical care medicine*
Kaplan, J. M., & Wong, H. R. (2010) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e3181e28876 · Cited by 102
Serum C-reactive protein as a marker for wellness assessment.
Kao, P. C., Shiesh, S. C., & Wu, T. J. (2006) · PubMed · Cited by 101
Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients
Bankier, B., Barajas, J., Martinez-Rumayor, A., & Januzzi, J. L. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn326 · Cited by 102
Inflammation in End-Stage Renal Disease – A Fire that Burns within
Stenvinkel, P. (2005) · KARGER eBooks · doi:10.1159/000085525 · Cited by 102
A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes
Stocker, D. J., Taylor, A. J., Langley, R. W., Jezior, M. R., & Vigersky, R. A. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.11.005 · Cited by 103
Lipids, atherosclerosis and CVD risk: Is CRP an innocent bystander?
Nordestgaard, B. G., & Zacho, J. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.07.005 · Cited by 101
Inflammatory Biomarkers in Acute Coronary Syndromes
Armstrong, E. J., Morrow, D. A., & Sabatine, M. S. (2006) · Circulation · doi:10.1161/circulationaha.105.595538 · Cited by 103
Self-citation
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration
Blanco‐Colio, L. M., Martı́n-Ventura, J. L., de Teresa, E., Farsang, C., Gaw, A., Gensini, G., Leiter, L. A., Langer, A., Martineau, P., & Egido, J. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.02.029 · Cited by 100
Danger Signaling in Atherosclerosis
Zimmer, S., Grebe, A., & Latz, E. (2015) · Circulation Research · doi:10.1161/circresaha.116.301135 · Cited by 106
The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines
Mora, S., Musunuru, K., & Blumenthal, R. S. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.109728 · Cited by 100
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
Lund, S. S., Tarnow, L., Stehouwer, C. D. A., Schalkwijk, C. G., Teerlink, T., Gram, J., Winther, K., Frandsen, M., Smidt, U., Pedersen, O. B., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0815 · Cited by 100
A Tale of Two Trials
Wiviott, S. D., de Lemos, J. A., Cannon, C. P., Blazing, M. A., Murphy, S. A., McCabe, C. H., Califf, R. M., & Braunwald, E. (2006) · Circulation · doi:10.1161/circulationaha.105.586347 · Cited by 97
Self-citation
Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide–Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia
Cheriyan, J., Webb, A. J., Sarov‐Blat, L., Elkhawad, M., Wallace, S. M. L., Maki-Petaja, K. M., Collier, D., Morgan, J., Fang, Z., Willette, R. N., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.971986 · Cited by 101
Interleukin-1α Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease
Schunk, S. J., Triem, S., Schmit, D., Zewinger, S., Sarakpi, T., Becker, E., Hütter, G., Wrublewsky, S., Küting, F., Hohl, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053547 · Cited by 101
Coffee or tea: Anti-inflammatory properties in the context of atherosclerotic cardiovascular disease prevention
Surma, S., Sahebkar, A., & Banach, M. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106596 · Cited by 99
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque
Marfella, R., Prattichizzo, F., Sardu, C., Paolisso, P., D’Onofrio, N., Scisciola, L., Grotta, R. L., Frigé, C., Ferraraccio, F., Panarese, I., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.971 · Cited by 103
C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction
Devaraj, S., Yun, J.-M., Adamson, G. N., Galvez, J., & Jialal, I. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp249 · Cited by 99
Atherogenesis: the role of inflammation and infection
Mahmoudi, M., Curzen, N. P., & Gallagher, P. J. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02503.x · Cited by 99
Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients
Rosenson, R. S., Hislop, C., Elliott, M. D., Stasiv, Y., Goulder, M. A., & Waters, D. D. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.015 · Cited by 95
The negative effects of hydrogenated trans fats and what to do about them
Kummerow, F. A. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.009 · Cited by 105
Statin treatment, oxidative stress and inflammation in a Danish population
Sørensen, A. L., Hasselbalch, H. C., Nielsen, C. H., Poulsen, H. E., & Ellervik, C. (2018) · Redox Biology · doi:10.1016/j.redox.2018.101088 · Cited by 97
Has the association between saturated fatty acids, serum cholesterol and coronary heart disease been over emphasized?
Parodi, P. W. (2009) · International Dairy Journal · doi:10.1016/j.idairyj.2009.01.001 · Cited by 99
Oxidant stress, inflammation and atherogenesis
Davı̀, G., & Falco, A. (2005) · Lupus · doi:10.1191/0961203305lu2216oa · Cited by 97

Authors: Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Ridker, Paul M
Cannon, Christopher P.
Morrow, David
Rifai, Nader
Rose, Lynda M.
Pfeffer, Marc A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-01-06
Volume: 352
Issue: 1
Pages: 20-28
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa042378
OpenAlex: W2118154631
Cited by: 2,292
References: 28
Citations by year: 2026: 32 · 2025: 46 · 2024: 47 · 2023: 52 · 2022: 70 · 2021: 58 · 2020: 74 · 2019: 64 · 2018: 72 · 2017: 54 · 2016: 78 · 2015: 62 · 2014: 67 · 2013: 93 · 2012: 88
FWCI: 282.76
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: C-reactive protein, statin therapy, LDL cholesterol, atorvastatin, pravastatin, acute coronary syndrome, reinfarction, coronary death, cardiovascular risk, lipid-lowering targets
MeSH terms: Atorvastatin, Gatifloxacin, Anticholesteremic Agents, C-Reactive Protein, Coronary Disease, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Risk Factors, Biomarkers, Incidence, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fluoroquinolones, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

C-Reactive Protein Levels and Outcomes after Statin Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks